16 new chief medical officers in March

Here are 16 new chief medical officers Becker's has reported on since March 2:

1. Keith Vollstedt, MD, was named chief medical officer of the Western Iowa region of Des Moines, Iowa-based MercyOne, which treats patients at 230 locations throughout Iowa and Nebraska.
2. Emil Kuriakose, MD, was named chief medical officer of Terns Oncology, a division of clinical-stage biopharmaceutical company Terns Pharmaceuticals.
3. Aharon Sareli, MD, was named chief medical officer of Hollywood, Fla.-based Memorial Healthcare System, and Holly Neville, MD, was appointed associate chief medical officer.
4. Stanley Fiel, MD, was appointed chief medical officer of Morristown (N.J.) Medical Center.
5. Mary Bridge Children's Hospital and Health Network in Tacoma, Wash., appointed two chief medical officers to lead the health system, with Vanessa Carroll, MD, serving as the hospital's new chief medical officer and Barbara Thompson, MD, serving as chief medical officer of Mary Bridge Children's Health Network.
6. Sean Martin, MD, was appointed chief medical officer of Oscar Health, the first health insurance company built around a full stack technology platform.
7. W. Michael Korn, MD, was named chief medical officer for oncology for medical genetics company Invitae.
8. Chelsea Hospital in Michigan has appointed Fazleomar Mahmood, MD, chief medical officer.
9. William Plauth, MD, was named chief medical officer of Reno, Nev.-based Renown Health.
10. Ray Gensinger, MD, was appointed senior vice president and chief medical officer of Tegria.
11. Lorna Gober, MD, was named chief medical officer of Vancouver, Wash.-based PeaceHealth's Northwest network. 
12. Mill Brown, MD, was appointed chief medical officer of Spring Health, the developer of a digital mental healthcare platform.
13. Anita Toussi, MD, PhD, was named chief medical officer of the Centura St. Catherine Hospitals of Southwest Kansas. 
14. Srdan Verstovsek, MD, PhD, was appointed chief medical officer of Kartos Therapeutics, a clinical stage biopharmaceutical company developing therapeutics for patients with cancer.